financetom
Business
financetom
/
Business
/
BCB Bancorp's Q2 net income rises to $3.6 mln
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
BCB Bancorp's Q2 net income rises to $3.6 mln
Jul 28, 2025 5:20 AM

Overview

* BCB Bancorp ( BCBP ) reports Q2 net income of $3.6 mln, recovering from Q1 net loss

* Net interest margin for Q2 improves to 2.80% from 2.60% in Q2 2024

* Provision for credit losses in Q2 decreases to $4.9 mln from $20.8 mln in Q1 2025

Outlook

* Company remains positive on medium to long-term outlook despite short-term impacts

* BCB Bancorp ( BCBP ) addressing asset quality challenges aggressively

* Company sees increased credit risk in cannabis loan portfolio

* No specific revenue or EPS guidance provided for future quarters

Result Drivers

* NET INTEREST MARGIN - Expansion to 2.80% driven by decreased cost of interest-bearing liabilities

* CREDIT LOSS PROVISION - Significant reduction to $4.9 mln from $20.8 mln in Q1 2025

* ASSET QUALITY - Ongoing efforts to address asset quality challenges, supporting future profitability

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 EPS $0.18

Q2 Net $3.60

Income mln

Q2 $0.16

Dividend

Q2 Net 2.8%

Interest

Margin

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Why Is Nano-Cap Silo Pharma Stock Skyrocketing On Tuesday?
Why Is Nano-Cap Silo Pharma Stock Skyrocketing On Tuesday?
Jul 16, 2024
Silo Pharma Inc ( SILO ) shares are trading higher on Tuesday on a high session volume of over 87 million. The company entered into an exclusive global license agreement to further develop, manufacture, and commercialize its Alzheimer’s drug SPC-14. Silo intends to utilize the FDA’s streamlined 505(b)(2) pathway for SPC-14, which would shorten clinical timelines and reduce drug development...
Update: Market Chatter: US Antitrust Regulator Seeking Details on Amazon's Deal With AI Firm Adept
Update: Market Chatter: US Antitrust Regulator Seeking Details on Amazon's Deal With AI Firm Adept
Jul 16, 2024
10:50 AM EDT, 07/16/2024 (MT Newswires) -- (Updates with Amazon ( AMZN ) declining to comment in the fourth paragraph.) The US Federal Trade Commission is asking Amazon.com ( AMZN ) for details on a deal to hire senior executives from artificial intelligence company Adept, Reuters reported Tuesday, citing an unnamed source familiar with the matter. On June 28, Adept...
Digimarc Names Katie Kool as Chair
Digimarc Names Katie Kool as Chair
Jul 16, 2024
10:49 AM EDT, 07/16/2024 (MT Newswires) -- Digimarc ( DMRC ) said Tuesday it has named Katie Kool as the new chair of its board. Kool succeeds Alicia Syrett, who was chair since 2020, the company said, adding Kool has been on its board since 2022. Price: 34.33, Change: +0.96, Percent Change: +2.88 ...
Vertex Pharmaceuticals, Genomics Extend Drug Discovery, Development Collaboration by 3 Years
Vertex Pharmaceuticals, Genomics Extend Drug Discovery, Development Collaboration by 3 Years
Jul 16, 2024
10:56 AM EDT, 07/16/2024 (MT Newswires) -- Vertex Pharmaceuticals ( VRTX ) and Genomics are extending their collaboration by three years to discover and develop precision medicines using genetics and machine learning, Genomics said Tuesday. The collaboration, which started in 2018 and was previously extended in 2021, will now continue until 2026, according to Genomics. The company also said it...
Copyright 2023-2026 - www.financetom.com All Rights Reserved